Maxwealth CSI All Share Medical Apparatus And Instruments ETF(159883) Rises 2.08% Intraday,Institutions: Long-Term Market Size to Grow Significantly

NewTimeSpace News: As of 14:13 on April 1, 2026, the CSI All-Share Medical Devices Index (H30217) surged 2.32%. Component stocks posted strong gains: Kangtuo Medical rose 12.02%, Hiteker Medical 11.37%, Jinbo Bio 11.34%, followed by Regenex Biotech, Jiu'an Medical and other stocks.Maxwealth CSI All Share Medical Apparatus And Instruments ETF(159883) rose 2.08% to 0.49 yuan per share. Over the longer term, as of March 31, 2026, the ETF had risen 1.91% in the past week, ranking 2nd among 4 comparable funds. (Stocks listed above are index constituents only and do not constitute specific investment recommendations.)

In terms of liquidity,Maxwealth CSI All Share Medical Apparatus And Instruments ETFrecorded an intraday turnover rate of 2.54% with a trading volume of 144 million yuan. As of March 31, its average daily trading volume in the past month stood at 149 million yuan, ranking first among comparable funds.

In terms of scale, the ETF’s scale increased by 3.809 billion yuan in the past year, marking significant growth, with new scale ranking in the top 25% among comparable funds. (Data source: Wind)

In terms of shares, the ETF’s shares increased by 4.043 billion units in March, showing notable growth, with new shares ranking in the top 25% among comparable funds. (Data source: Wind)

Data showed that leveraged funds continued to allocate to the ETF. Its net margin purchase on the previous trading day reached 2.8463 million yuan, with a latest margin balance of 241 million yuan. (Data source: Wind)

In terms of profitability, as of March 31, 2026, since inception, the ETF’s highest monthly return was 22.97%, longest consecutive rising months 4 months, longest consecutive rise 19.79%, and average return in rising months 4.57%. As of March 31, 2026, the ETF had outperformed the benchmark by an annualized return of 1.07% in the past two years, ranking in the top 2 of 4 comparable funds.

In terms of drawdown, as of March 31, the ETF’s relative benchmark drawdown year-to-date was 0.16%.

On the fee front, the management fee rate is 0.50% and the custodian fee rate 0.10%, which is relatively low among comparable funds.

In terms of tracking accuracy, as of March 31, the one-month tracking error was 0.009%, the highest among comparable funds.

Notably, the CSI All-Share Medical Devices Index tracked by the fund is at a historically low valuation. Its latest price-to-book ratio (PB) is 2.86 times, lower than 91.39% of the time in the past year, indicating outstanding valuation attractiveness.

Maxwealth CSI All Share Medical Apparatus And Instruments ETFclosely tracks the CSI All-Share Medical Devices Index. To reflect the overall performance of companies in different sectors within the CSI All-Share Index and provide investors with analytical tools, the CSI All-Share Index constituents are divided into 11 first-level industries, 35 second-level industries, over 90 third-level industries and over 200 fourth-level industries under the CSI Industry Classification. The CSI All-Share Sector Indices are then compiled using all securities in each level of industry as index constituents.

As of March 31, 2026, the top 10 constituents of the CSI All-Share Medical Devices Index (H30217) were Mindray Medical, United Imaging Healthcare, Intco Medical, Jiu'an Medical, HTM Medical, Lepu Medical, Yuwell Medical, Snibe Biotech, Amicula and Forever Med, accounting for 44.02% of the index weight. (Stocks listed above are index constituents only and do not constitute specific investment recommendations.)

Huayuan Securities stated that China's medical device market size is expected to grow to 16.6 trillion yuan by 2030, with considerable growth potential in the medical consumables sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.